Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Bio-Technology General signs U.S. marketing agreement with Akorn for BioLon

April 15, 1998

New ocular agents described by Novartis

March 30, 1998

QLT and Ciba Vision initiate phase IIIb verteporfin trial

March 20, 1998

FDA approves ocular antiinflammatory agent

March 11, 1998

Preliminary results reported from phase II trials of Vitrase

March 6, 1998

Improved vision in AMD patients in phase I/II using PhotoPoint technology

Feb. 25, 1998

Allergan's new antiglaucoma agents

Feb. 20, 1998

Genetic basis for RP described

Feb. 5, 1998

FDA issues approvable letter for BioLon

Feb. 4, 1998

Novo Nordisk discloses peripheral muscarinic cholinergic agonists

Jan. 13, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...